Nasopharyngeal Streptococcus Pneumoniae Carriage
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00471822|
Recruitment Status : Completed
First Posted : May 10, 2007
Results First Posted : November 20, 2013
Last Update Posted : November 20, 2013
Primary Objective: Evaluation of the
- Carriage rate of Streptococcus pneumoniae in the nasopharynx of children
- Carriage rate and distribution of Streptococcus pneumoniae serotypes
- Estimation of prevalence rate of antibiotic-resistant Streptococcus pneumoniae strains
- Distribution of Staphylococcus aureus strain
- The influence of risk factors in the Streptococcus pneumoniae carriage rate in children
|Condition or disease|
|Streptococcus Pneumoniae Infections|
|Study Type :||Observational|
|Actual Enrollment :||9707 participants|
|Official Title:||An Evaluation of Streptococcus Pneumoniae Serotype Carriage Rate for Nasopharyngeal Carriage in Taiwanese Children Attending Pediatric Clinics in Hospitals, Day Care Centers, or Kindergartens|
|Study Start Date :||July 2005|
|Actual Primary Completion Date :||December 2010|
|Actual Study Completion Date :||December 2010|
- Percentage of Participants With Carriage of Streptococcus Pneumoniae in Nasopharynx [ Time Frame: Day 1 ]Swab cultures obtained from the nasopharynx of participants were tested for the presence of streptococcus pneumoniae strains.
- Serotype Distribution of Streptococcus Pneumoniae Isolates [ Time Frame: Day 1 ]Streptococcus pneumoniae in swab culture of nasopharynx were serotyped. The assessment included 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F, non-vaccine, non-typable and missing serotypes. Percentage of participants under different vaccine serotypes in identified isolates of streptococcus pneumonia are reported.
- Antibiotic-Resistant Streptococcus Pneumoniae Strains [ Time Frame: Day 1 ]Antibiotic resistance is defined as in vitro inhibition of a particular bacterial strain by a concentration of the drug associated with high likelihood of therapeutic failure. Antibiotic resistance for streptococcus pneumoniae was assessed against Penicillin, Cefotaxime, Levofloxacin, Erythromycin and combination of Trimethoprim with sulfamethoxazole. The standard breakpoint value (microbial growth inhibition zone) for Penicillin, Cefotaxime, Levofloxacin, Erythromycin and combination of Trimethoprim with sulfamethoxazole was not more than 8, 4, 13, 15 and 15 millimeter (mm) respectively. Percentage of participants with antibiotic-resistant streptococcus pneumoniae strains are reported. The same participant may have streptococcus pneumoniae strains which is resistance to more than one antibiotic.
- Percentage of Participants With Carriage of Staphylococcus Aureus in Nostril [ Time Frame: Day 1 ]Swab cultures obtained from the nostril of participants were tested for the presence of Staphylococcus aureus strains.
- Percentage of Participants With Carriage of Streptococcus Pneumoniae Based on Risk Factors [ Time Frame: Day 1 ]Participants for carriage of streptococcus pneumoniae were analyzed with respect to various risk factors which included number of bathrooms, number of siblings in the family (multiple siblings), size of the house in meter square (house area), frequency of hand wash in a day, bed sharing, smoking by family member, child breast feeding (breast milk practice), daycare attendance, vaccination for flu and pneumococcus, history of otitis media and upper respiratory infection (URI), antibiotic use and influenza virus infection.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00471822
|Pfizer Investigational Site|
|Taoyuan, Taiwan, 333|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|